All Stories

  1. Conducting and Reporting Meta-analysis: A Checklist for Reviewers
  2. Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
  3. Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis
  4. Using machine learning to assess cardiovascular risk in T2DM patients without established cardiovascular disease: The MARK-2 analysis
  5. A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
  6. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis
  7. The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis
  8. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS)
  9. Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism –an Integrated Diabetes and Endocrine Academy (IDEA) consensus guideline
  10. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
  11. A target HbA1c between 7 – 7.7% reduces macrovascular events in T2D regardless of duration of diabetes – a meta-analysis of randomized controlled trials
  12. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
  13. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
  14. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis
  15. “Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"
  16. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis
  17. Impact of complete lockdown on total infection and death rates: A hierarchical cluster analysis
  18. Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)
  19. Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis
  20. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis
  21. Impact of complete lock-down on total infection and death rates: A hierarchical cluster analysis
  22. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
  23. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis
  24. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis
  25. Frequency of testing for COVID 19 infection and the presence of higher number of available beds per country predict outcomes with the infection, not GDP of the country – A descriptive statistical analysis
  26. Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting
  27. Teneligliptin and “Thorough QTc study”: thorough enough?
  28. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
  29. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
  30. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
  31. Hypoglycaemia and CV risk: Perceptions and reality
  32. Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
  33. India suspends pioglitazone: Is it justified?
  34. Treat-to-target trials in diabetes
  35. Pioglitazone – Do we really need it to manage type 2 diabetes?
  36. Polyendocrine syndromes (revision number 19)
  37. Hyperprolactinaemia (revision number 8)
  38. Pioglitazone—Do we really need it to manage type 2 diabetes?
  39. Hypercortisolism (revision number 36)
  40. Quantitative vibration perception threshold in assessing diabetic neuropathy: Is the cut-off value lower for Indian Subjects? [Q-VADIS Study]
  41. Critical appraisal of the recent data published on the link between insulin and cancer